Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05760248 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity
A Phase 2 study, sponsored by 10xBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT05760248: Completed Phase 2 study, sponsored by 10xBio.
NCT05760248 is a Phase 2 study that has completed, run by 10xBio. The registered enrollment target is 13 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05760248, a Phase 2 study, has completed, sponsored by 10xBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to test the safety and effectiveness of an injection study drug in decreasing bilateral flank adiposity. The main question it aims to answer is: •How safe and effective is the injection study drug in removing bilateral flank adiposity compared to a placebo? Participants will be: * Be given injections every month for 5 months over the right and left flanks. * Be asked to be seen in the clinic for 13 visits and 3 phone call visits during a duration of 1 year.
Primary Outcome
Change from Baseline until end of study. Volumetric measurements will be obtained on each right and left flanks thru a standard photographic assessment.
Interventions
- DRUG 10XB-101 Solution for Injection, 6.0%
- DRUG Placebo Solution for Injection (no active ingredient)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-05-04 |
| Est. Completion | 2025-01-22 |
| Phase | Phase 2 |
What the finished NCT05760248 record still lists
NCT05760248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which 10XB-101 Solution for Injection, 6.0% is the first listed.
NCT05760248 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05760248 about?
NCT05760248 is a clinical study titled "Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity". The goal of this clinical trial is to test the safety and effectiveness of an injection study drug in decreasing bilateral flank adiposity. The main question it aims to answer is: •How safe and effective is the injection study drug in removing bilateral flank adiposity compared to a placebo? Part...
What is the current status of trial NCT05760248?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2023-05-04. Estimated completion is 2025-01-22.
What interventions are being tested in trial NCT05760248?
The interventions under investigation include: 10XB-101 Solution for Injection, 6.0% (DRUG), Placebo Solution for Injection (no active ingredient) (DRUG).
Who is sponsoring clinical trial NCT05760248?
This trial is sponsored by 10xBio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05760248's enrollment target sits among peer trials
13 1947th of 2000 higher than 53 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI